Within this category, LSD1 inhibitors constitute a promising epigenetic approach to treat AML, and currently a number of clinical trials are aiming to treat refractory AML by blocking LSD1 activity (15, 18). This evidence concerns the gene KDM1A and acute myeloid leukemia.